3-[(2E,6E)-3,7,11-三甲基十二碳-2,6,10-三烯基]硫基-2H-1,2,4-三唑 | 156604-45-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 3-[(2E,6E)-3,7,11-三甲基十二碳-2,6,10-三烯基]硫基-2H-1,2,4-三唑
• 英文名称: Farnesylthiotriazole
• 英文别名: 5-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanyl-1H-1,2,4-triazole
• CAS: 156604-45-4
• 化学式: C₁₇H₂₇N₃S
• 分子量: 305.5
• InChiKey: QFXNCKFWHATRCH-XGGJEREUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  66.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PKC activators and combinations thereof
  申请人：Cognitive Research Enterprises, Inc.

  公开号：US10821079B2

  公开（公告）日：2020-11-03

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。该公开进一步涉及这些组合物的组成、试剂盒、用途和方法。
• PKC ACTIVATORS AND COMBINATIONS THEREOF
  申请人：BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE

  公开号：US20140315990A1

  公开（公告）日：2014-10-23

  The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.

  本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、套件、用途和方法。
• Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
  申请人：Blanchette Rockefeller Neurosciences Institute

  公开号：EP2737904A2

  公开（公告）日：2014-06-04

  The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.

  本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）、脑源性神经营养因子（BDNF）或其他神经营养因子的促进剂治疗中风的方法。具体而言，本发明提供了治疗中风的方法，包括以下步骤：确定中风患者，并向所述患者施用一定量的药物组合物，该药物组合物包含蛋白激酶 C (PKC) 激活剂或 4-甲基邻苯二酚乙酸 (MCBA) 和药学上可接受的载体，可有效治疗中风的至少一种症状。
• THERAPEUTIC EFFECTS OF BRYOLOGS ON HEAD TRAUMA-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY
  申请人：Blanchette Rockefeller Neurosciences Institute

  公开号：EP2959914A1

  公开（公告）日：2015-12-30

  The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brainderived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma.

  本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）、脑神经营养因子（BDNF）或其他神经营养因子的促进剂治疗头部创伤的方法。具体地说，本发明提供了治疗头部创伤的方法，包括以下步骤：确定遭受头部创伤的受试者，并向所述受试者施用一定量的药物组合物，该药物组合物包含蛋白激酶C（PKC）激活剂或4-甲基邻苯二酚乙酸（MCBA）和药学上可接受的载体，可有效治疗头部创伤的至少一种症状。
• Treatment of depressive disorders
  申请人：Blanchette Rockefeller Neuroscience Institute

  公开号：US10010584B2

  公开（公告）日：2018-07-03

  The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds to treat depressive disorders.

  本发明提供了使用碳酸酐酶激活剂、蛋白激酶 C 激活剂和 FGF-18 治疗抑郁障碍的方法。本发明还涉及用于筛选和鉴定治疗抑郁障碍的化合物的改良动物模型和方法。